Cardio Diagnostics Holdings, Inc. (CDIO)
Cardio Diagnostics Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Chicago, IL, US. The stock last traded at $1.95, up 6.28% on the session, giving a market capitalisation of $5.8M. On trailing twelve-month figures it carries a trailing P/E of -0.67, a net margin of -44771.8%. Its beta of 2.22 implies it has historically moved more than the broad market.
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Cardio Diagnostics Holdings, Inc. is most often compared with the following Healthcare names: